|HOLD||$82.770||UNKNOWN||NORTH AMERICAN - LARGE||Yes|
This pulled back because it had to reduce its earnings guidance for this upcoming year. They had been guiding for 10%-14% growth for the next few years, and have had to reduce that to 10% going forward. This is because their drug retail side has been excluded in certain pharmacy networks. The valuation is very attractive at about 13 or 14 times forward earnings. A well-managed company.
CEO & Managing Director, GlobeInvest Capital Management